Ignite Proteomics, a subsidiary of IMAC Holdings, has announced a one-year collaboration with Vanderbilt University Medical Center (VUMC) aimed at enhancing the understanding of how breast cancer cells avoid detection by the immune system. This partnership will utilize VUMC’s clinical samples to characterize specific protein-signaling pathways associated with breast tumors. As part of the collaboration,...
Aclarion Inc. (Nasdaq: ACON), a Broomfield-based healthcare technology company, reported a 132% year-over-year increase in scan volume for its flagship product, Nociscan, from Q2 2024 to Q2 2025. This marks the company’s first time achieving two consecutive quarters of scan growth. Nociscan uses proprietary AI algorithms and magnetic resonance spectroscopy to help physicians identify the...
PharmaJet Inc. has signed a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority and EVA Pharma to explore needle-free delivery of vaccines in Egypt’s routine immunization program. This agreement was formalized during the African Health ExCon health care conference held in Cairo on June 26. The collaboration aims to integrate needle-free technology for...
Cerapedics Inc. successfully treated the first U.S. patient using its newly approved bone graft designed to accelerate lumbar fusion. This marks a significant milestone following the approval from the U.S. Food and Drug Administration (FDA) for the PearlMatrix P-15 Peptide Enhanced Bone Graft. The procedure was carried out at AdventHealth Avista in Louisville, Colo., by...
Aclarion Inc. enrolled the first patient in its CLARITY trial, aimed at assessing the impact of its Nociscan technology on surgical treatments for chronic low back pain. The initial participant was enrolled at the Texas Back Institute, recognized for its advancements in spine care. The CLARITY trial is a randomized clinical study designed to evaluate...
PharmaJet Inc. has partnered with Immuno Cure to develop a needle-free HIV therapeutic DNA vaccine. The agreement, signed on June 16, 2025, during the BIO International Convention in Boston, will utilize PharmaJet’s Tropis system in a human clinical trial for their ICVAX vaccine. This collaboration follows the success of an earlier Phase 1 trial of...
Aclarion Inc., a Broomfield health care technology company, has reported that UHealth — University of Miami Health System and the University of Miami Miller School of Medicine will be a site for its CLARITY clinical trial. This trial aims to evaluate the effectiveness of Nociscan, a solution designed to assist physicians in identifying sources of...
Highridge Medical has completed the sale of its Bone Healing division to Avista Healthcare Partners. This move aims to help the company focus exclusively on its Spine business and enhance long-term growth through increased investment in innovation and commercial capabilities. The sale proceeds will be directed towards portfolio innovation and expanding the company’s commercial reach....
Aclarion Inc. (Nasdaq: ACON, ACONW) has reported that the Keck Medical Center of USC has joined the CLARITY (Chronic Low Back Pain Randomized Independent Trial Study) as a trial site. The USC Spine Center specializes in treating complex spine conditions using advanced technologies. The CLARITY trial is a randomized clinical study aimed at demonstrating the...
Terumo BCT has reported that Join Parachute will implement the Rika Plasma Donation System, designed to enhance the plasma donation experience and increase donor comfort. This next-generation plasma collection system aims to improve access to lifesaving therapies by rethinking the donation process. Join Parachute is focused on providing greater access to plasma through a donor-first...
Aclarion Inc. (Nasdaq: ACON, ACONW) has reported that the Texas Back Institute (TBI) will serve as a new site for the CLARITY (C hronic L ow b A ck pain R andomized I ndependent T rial stud Y) clinical trial. TBI is widely recognized for its contributions to spine technology, education and patient care. The...
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology company, has reported that Advocate Aurora Research Institute, part of Advocate Health, will participate as a site in the CLARITY (Chronic Low Back pain Randomized Independent Trial studY) trial. The trial aims to demonstrate the clinical and economic value of Nociscan in spine surgery. “Advocate...